Literature DB >> 11809648

First trial of the HIV-1 vaccine in Africa: Ugandan experience.

Roy D Mugerwa1, Pontiano Kaleebu, Peter Mugyenyi, Edward Katongole-Mbidde, David L Hom, Rose Byaruhanga, Robert A Salata, Jerrold J Ellner.   

Abstract

Entities:  

Keywords:  Biomedical and Behavioral Research

Mesh：

Substances：

Year:  2002        PMID： 11809648      PMCID： PMC1122137          DOI： 10.1136/bmj.324.7331.226

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  10 in total

1.  Developing AIDS vaccine trials educational programs in Uganda.

Authors:  J W McGrath; D Mafigiri; M Kamya; K George; R Senvewo; G Svilar; M Kabugo; E Mugisha
Journal:  J Acquir Immune Defic Syndr       Date:  2001-02-01       Impact factor: 3.731

Review 2.  Accelerating the development and future availability of HIV-1 vaccines: why, when, where, and how?

Authors:  J Esparza; N Bhamarapravati
Journal:  Lancet       Date:  2000-06-10       Impact factor: 79.321

3.  HIV-1 risk and vaccine acceptability in the Ugandan military.

Authors:  D L Hom; J L Johnson; P Mugyenyi; R Byaruhanga; C Kityo; A Louglin; G M Svilar; M Vjecha; R D Mugerwa; J J Ellner
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1997-08-15

4.  Human immunodeficiency virus vaccine development in developing countries: are efficacy trials feasible?

Authors:  J L Excler; C Beyrer
Journal:  J Hum Virol       Date:  2000 Jul-Aug

Review 5.  HIV vaccine development for the world: an idea whose time has come?

Authors:  S Berkley
Journal:  AIDS Res Hum Retroviruses       Date:  1998-10       Impact factor: 2.205

6.  Bioethics and local circumstances.

Authors:  E Mbidde
Journal:  Science       Date:  1998-01-09       Impact factor: 47.728

7.  Behavioral research contributions to planning and conducting HIV vaccine efficacy studies.

Authors:  L R Temoshok
Journal:  AIDS Res Hum Retroviruses       Date:  1994       Impact factor: 2.205

8.  Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection. AGIS Group and L'Agence Nationale de Recherches sur Le Sida.

Authors:  D Salmon-Céron; J L Excler; L Finkielsztejn; B Autran; J C Gluckman; D Sicard; T J Matthews; B Meignier; C Valentin; R El Habib; C Blondeau; M Raux; C Moog; J Tartaglia; P Chong; M Klein; B Milcamps; F Heshmati; S Plotkin
Journal:  AIDS Res Hum Retroviruses       Date:  1999-05-01       Impact factor: 2.205

9.  Ethical, behavioral, and social aspects of HIV vaccine trials in developing countries.

Authors:  P Lurie; M Bishaw; M A Chesney; M Cooke; M E Fernandes; N Hearst; E Katongole-Mbidde; S Koetsawang; C P Lindan; J Mandel
Journal:  JAMA       Date:  1994-01-26       Impact factor: 56.272

10.  The safety and use of canarypox vectored vaccines.

Authors:  S A Plotkin; M Cadoz; B Meignier; C Méric; O Leroy; J L Excler; J Tartaglia; E Paoletti; E Gonczol; G Chappuis
Journal:  Dev Biol Stand       Date:  1995
  10 in total
  9 in total

1.  Balancing collective responsibility, individual opportunities and risks: a qualitative study on how police officers reason around volunteering in an HIV vaccine trial in Dar es Salaam, Tanzania.

Authors:  Edith A M Tarimo; Anna Thorson; Thecla W Kohi; Joachim Mwami; Muhammad Bakari; Eric Sandström; Asli Kulane
Journal:  BMC Public Health       Date:  2010-05-28       Impact factor: 3.295

2.  What led to the Nigerian boycott of the polio vaccination campaign?

Authors:  Ayodele Samuel Jegede
Journal:  PLoS Med       Date:  2007-03       Impact factor: 11.069

3.  The Medical Research Council (UK)/Uganda Virus Research Institute Uganda Research Unit on AIDS--'25 years of research through partnerships'.

Authors:  P Kaleebu; A Kamali; J Seeley; A M Elliott; E Katongole-Mbidde
Journal:  Trop Med Int Health       Date:  2014-10-29       Impact factor: 2.622

4.  Perception of potential harm and benefits of HIV vaccine trial participation: A qualitative study from urban Tanzania.

Authors:  Edith A M Tarimo; Joel Ambikile; Patricia Munseri; Muhammad Bakari
Journal:  PLoS One       Date:  2019-11-08       Impact factor: 3.240

Review 5.  COVID-19 preparedness: capacity to manufacture vaccines, therapeutics and diagnostics in sub-Saharan Africa.

Authors:  Bisi Bright; Chinedum Peace Babalola; Nadia Adjoa Sam-Agudu; Augustine Anayochukwu Onyeaghala; Adebola Olatunji; Ufuoma Aduh; Patrick O Sobande; Trevor A Crowell; Yenew Kebede Tebeje; Sunny Phillip; Nicaise Ndembi; Morenike Oluwatoyin Folayan
Journal:  Global Health       Date:  2021-03-03       Impact factor: 4.185

6.  Young at risk-people in Maputo City, Mozambique, present a high willingness to participate in HIV trials: Results from an HIV vaccine preparedness cohort study.

Authors:  Igor P U Capitine; Ivalda B Macicame; Artur M Uanela; Nilesh B Bhatt; Adam Yates; Mark Milazzo; Chiaka Nwoga; Trevor A Crowell; Nelson L Michael; Merlin L Robb; Ilesh V Jani; Arne Kroidl; Christina S Polyak; Caroline De Schacht
Journal:  PLoS One       Date:  2021-12-02       Impact factor: 3.240

7.  Sociodemographic factors associated with acceptance of COVID-19 vaccine and clinical trials in Uganda: a cross-sectional study in western Uganda.

Authors:  Isaac Echoru; Patricia Decanar Ajambo; Emmanuel Keirania; Edmund E M Bukenya
Journal:  BMC Public Health       Date:  2021-06-10       Impact factor: 3.295

8.  African AIDS vaccine programme for a coordinated and collaborative vaccine development effort on the continent.

Authors:  Pontiano Kaleebu; Alash'le Abimiku; Shenaaz El-Halabi; Sinata Koulla-Shiro; Nicole Mamotte; Souleymane Mboup; Roy Mugerwa; John Nkengasong; Coumba Toure-Kane; Tim Tucker; Douglas Wassenaar; Carolyn Williamson; Dawit Wolday
Journal:  PLoS Med       Date:  2008-12-02       Impact factor: 11.069

Review 9.  Major Scientific Hurdles in HIV Vaccine Development: Historical Perspective and Future Directions.

Authors:  Tiza Ng'uni; Caroline Chasara; Zaza M Ndhlovu
Journal:  Front Immunol       Date:  2020-10-28       Impact factor: 7.561
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.